Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn's disease patients who failed infliximab therapy: the Italian Society of Pediatric …
Background Adalimumab (Ada) treatment is an available option for pediatric Crohn's
disease (CD) and the published experience as rescue therapy is limited. Objectives We …
disease (CD) and the published experience as rescue therapy is limited. Objectives We …
Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease
LS Conklin, B Cohen, L Wilson, C Cuffari… - Nature Reviews …, 2010 - nature.com
Abstract Background. A 17-year-old white male with Crohn's disease who was receiving
maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented …
maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented …
[HTML][HTML] Recent advances in understanding and managing pediatric inflammatory bowel disease
B Gurram, AS Patel - F1000Research, 2019 - ncbi.nlm.nih.gov
The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic
advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists …
advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists …
[HTML][HTML] Tumour necrosis factor‐alpha antagonists for treatment of paediatric Crohn's disease
JC Gana, A Sepúlveda, E Orlanski-Meyer… - The Cochrane …, 2022 - ncbi.nlm.nih.gov
Tumour necrosis factor‐alpha antagonists for treatment of paediatric Crohn’s disease - PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Etanercept in juvenile psoriasis
FC Beikert, M Augustin, MA Radtke - Der Hautarzt, 2012 - Springer
Zusammenfassung Hintergrund Mit einer Prävalenz von 0, 71% ist die Psoriasis eine der
häufigsten kindlichen Dermatosen. Patienten und Methoden Nach zuvor frustranen …
häufigsten kindlichen Dermatosen. Patienten und Methoden Nach zuvor frustranen …
The development and assessment of biological treatments for children
The development of biological agents with specific immunological targets has revolutionized
the treatment of a wide variety of paediatric diseases where traditional immunosuppressive …
the treatment of a wide variety of paediatric diseases where traditional immunosuppressive …
Pharmacological treatments and infectious diseases in pediatric inflammatory bowel disease
V Dipasquale, C Romano - Expert review of gastroenterology & …, 2018 - Taylor & Francis
Introduction: The incidence of pediatric inflammatory bowel disease (IBD) is rising, as is the
employment of immunosuppressive and biological drugs. Most patients with IBD receive …
employment of immunosuppressive and biological drugs. Most patients with IBD receive …
Рекомендации по диагностике и лечению болезни Крона у детей (проект)
ЕА Корниенко, АС Потапов, СВ Бельмер… - Вопросы детской …, 2017 - elibrary.ru
Рекомендации по диагностике и лечению болезни Крона у детей (проект) КОРЗИНА
ПОИСК НАВИГАТОР СЕССИЯ КОНТАКТЫ ИНФОРМАЦИЯ О ПУБЛИКАЦИИ eLIBRARY …
ПОИСК НАВИГАТОР СЕССИЯ КОНТАКТЫ ИНФОРМАЦИЯ О ПУБЛИКАЦИИ eLIBRARY …
Adalimumab for the treatment of pediatric Crohn's disease
Inflammatory bowel diseases are characterized by a chronic relapsing course, high
morbidity and impaired quality of life. Their incidence is rising, and about 25% of cases are …
morbidity and impaired quality of life. Their incidence is rising, and about 25% of cases are …
Терапевтический лекарственный мониторинг адалимумаба при воспалительных заболеваниях кишечника у детей
АС Илларионов, ТВ Радыгина, АС Потапов… - Вопросы детской …, 2021 - elibrary.ru
Цель. Оценить значимость терапевтического мониторинга концентрации адалимумаба
(ADA) и антител к нему при воспалительных заболеваниях кишечника (ВЗК) у детей …
(ADA) и антител к нему при воспалительных заболеваниях кишечника (ВЗК) у детей …